In 1990, Anderson carried out the first-ever clinical trial for gene therapy, utilizing a murine retroviral vector to introduce the adenosine deaminase (ADA) gene into T cells of children with severe combined immunodeficiency (SCID) [11]. Here, ADA is linked to severe combined immunodeficiency.